Carcinogenesis
|
phenotype |
Pathological Conditions, Signs and Symptoms; Neoplasms
|
Neoplastic Process
|
6243
|
355
|
0.100 |
None |
1.000 |
14 |
|
2004 |
2019 |
Hyperinsulinism
|
disease |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
620
|
64
|
0.420 |
None |
1.000 |
9 |
|
1986 |
2019 |
Streptozotocin Diabetes
|
disease |
Nutritional and Metabolic Diseases; Endocrine System Diseases
|
Experimental Model of Disease
|
112
|
|
0.300 |
None |
1.000 |
9 |
|
2004 |
2016 |
Alloxan Diabetes
|
disease |
Nutritional and Metabolic Diseases; Endocrine System Diseases
|
Experimental Model of Disease
|
112
|
|
0.300 |
None |
1.000 |
9 |
|
2004 |
2016 |
Diabetes Mellitus, Experimental
|
disease |
Nutritional and Metabolic Diseases; Endocrine System Diseases
|
Experimental Model of Disease
|
522
|
|
0.300 |
None |
1.000 |
9 |
|
2004 |
2016 |
Hyperglycemia, Postprandial
|
phenotype |
Nutritional and Metabolic Diseases
|
Finding
|
37
|
|
0.300 |
None |
1.000 |
8 |
|
1986 |
2018 |
Mammary Neoplasms
|
group |
Neoplasms; Skin and Connective Tissue Diseases
|
Neoplastic Process
|
2780
|
385
|
0.370 |
None |
1.000 |
8 |
|
2002 |
2014 |
Diabetes
|
disease |
Endocrine System Diseases
|
Disease or Syndrome
|
2359
|
710
|
0.080 |
None |
1.000 |
8 |
|
1996 |
2019 |
Compensatory Hyperinsulinemia
|
disease |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
30
|
2
|
0.300 |
None |
1.000 |
7 |
|
1986 |
2019 |
Fatty Liver
|
disease |
Digestive System Diseases
|
Disease or Syndrome
|
875
|
35
|
0.350 |
None |
1.000 |
7 |
|
2008 |
2020 |
Insulin Resistance
|
phenotype |
Nutritional and Metabolic Diseases
|
Pathologic Function
|
162
|
53
|
0.500 |
None |
1.000 |
7 |
|
2009 |
2019 |
Exogenous Hyperinsulinism
|
disease |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
26
|
|
0.300 |
None |
1.000 |
7 |
|
1986 |
2019 |
Endogenous Hyperinsulinism
|
disease |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
26
|
|
0.300 |
None |
1.000 |
7 |
|
1986 |
2019 |
Anorexia Nervosa
|
disease |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
202
|
72
|
0.060 |
None |
1.000 |
6 |
|
2002 |
2020 |
Neoplasm Metastasis
|
phenotype |
Pathological Conditions, Signs and Symptoms; Neoplasms
|
Neoplastic Process
|
6385
|
327
|
0.060 |
None |
0.833 |
6 |
|
2004 |
2019 |
Insulin Sensitivity
|
phenotype |
Nutritional and Metabolic Diseases
|
Pathologic Function
|
62
|
|
0.300 |
None |
1.000 |
6 |
|
2009 |
2019 |
Secondary malignant neoplasm of lymph node
|
disease |
Pathological Conditions, Signs and Symptoms; Neoplasms
|
Neoplastic Process
|
2825
|
188
|
0.060 |
None |
1.000 |
6 |
|
2006 |
2015 |
Metabolic Diseases
|
group |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
945
|
50
|
0.060 |
None |
1.000 |
6 |
|
2001 |
2018 |
Adenoma
|
group |
Neoplasms
|
Neoplastic Process
|
1183
|
103
|
0.050 |
None |
0.800 |
5 |
|
2002 |
2019 |
Tumor Progression
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Neoplastic Process
|
3865
|
72
|
0.040 |
None |
1.000 |
4 |
|
2007 |
2017 |
Triple-Negative Breast Carcinoma
|
disease |
Neoplasms; Skin and Connective Tissue Diseases
|
Neoplastic Process
|
1598
|
96
|
0.040 |
None |
1.000 |
4 |
|
2013 |
2018 |
Hypogonadotropic hypogonadism
|
disease |
Endocrine System Diseases
|
Disease or Syndrome
|
178
|
18
|
0.330 |
None |
1.000 |
4 |
|
1999 |
2015 |
Endometrial Carcinoma
|
disease |
Neoplasms; Female Urogenital Diseases and Pregnancy Complications
|
Neoplastic Process
|
1597
|
326
|
0.040 |
None |
1.000 |
4 |
|
2006 |
2017 |
Triple Negative Breast Neoplasms
|
disease |
Neoplasms; Skin and Connective Tissue Diseases
|
Neoplastic Process
|
1674
|
99
|
0.040 |
None |
1.000 |
4 |
|
2013 |
2018 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
disease |
|
Disease or Syndrome
|
15
|
3
|
0.040 |
None |
1.000 |
4 |
|
2018 |
2019 |